Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 5/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2688262 | 1.00 | CHRM2 (0.35) | CHRM2CHRM1CHRM4CHRM3CYP2D6 | |
| SCHEMBL2688263 | 1.00 | CHRM2 (0.35) | CHRM2CHRM1CHRM4CHRM3CYP2D6 | |
| SCHEMBL6898147 | 0.81 | CHRM2 (0.35) | CHRM2CHRM1CHRM4CHRM3CYP2D6 | |
| SCHEMBL19725575 | 0.78 | CHRM2 (0.40) | CHRM2CHRM1CHRM4CHRM3CYP2D6 | |
| SCHEMBL13820561 | 0.78 | CHRM2 (0.40) | CHRM2CHRM1CHRM4CHRM3CYP2D6 | |
| SCHEMBL2689882 | 0.77 | PPM1D (0.34) | — | |
| SCHEMBL2689885 | 0.77 | PPM1D (0.34) | — | |
| SCHEMBL17807032 | 0.75 | CHRM2 (0.47) | CHRM2CHRM1CHRM4CHRM3CYP2D6 | |
| SCHEMBL22006156 | 0.75 | CHRM2 (0.47) | CHRM2CHRM1CHRM4CHRM3CYP2D6 | |
| SCHEMBL28522654 | 0.75 | CHRM2 (0.47) | CHRM2CHRM1CHRM4CHRM3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180327354-A1 | Unnatural Analogues of Calcitriol and Uses Thereof | VIDASYM, LLC | 2018-11-15 | — | — | US | disclosed |
| US-20120115824-A1 | Vitamin D Receptor Agonists and Uses Thereof | VIDASYM, LLC (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115824-A1 | Vitamin D Receptor Agonists and Uses Thereof | VDR, CYP2R1, CYP24A1 | CHRM2 957/4885CHRM1 1081/4885CHRM4 1852/4885 |
| US-20180327354-A1 | Unnatural Analogues of Calcitriol and Uses Thereof | VDR, CYP2R1, CYP24A1 | CHRM2 1705/4885CHRM1 1912/4885CHRM4 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.